Literature DB >> 31836

HR 756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity.

Y A Chabbert, A J Lutz.   

Abstract

HR 756, the syn derivative of 7-[(2-(2-amino-4-thiazolyl)-2-methoxyimino)acetamido]cephalosporanic acid, is a new semisynthetic cephalosporin. It was 80 times more active than the anti derivative against beta-lactamase-producing strains of gram-negative bacteria. The range of inhibitory concentrations of HR 756 against gram-negative bacteria, including Haemophilus influenzae, susceptible or resistant to penicillins and cephalosporins was from 0.01 to 0.1 mug/ml. This activity was consistently higher than those observed with cephalothin, cephaloridine, cephalexin, and cefazolin. Nevertheless, some strains of Enterobacter cloacae were resistant. HR 756 showed very similar activity to that of ampicillin against group A streptococci and Streptococcus pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 31836      PMCID: PMC352545          DOI: 10.1128/AAC.14.5.749

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  [Inducible cephalosporinases from Proteus morganii].

Authors:  R Labia; M Guionie; C Fabre
Journal:  Biochimie       Date:  1976-11-13       Impact factor: 4.079

2.  Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents.

Authors:  M Finland; C Garner; C Wilcox; L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

3.  [Constitutive cephalosporinases from "Escherichia coli" (author's transl)].

Authors:  R Labia; G Brunet; M Guionie; A Philippon; M Heitz; J S Pitton
Journal:  Ann Microbiol (Paris)       Date:  1976 Nov-Dec

Review 4.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

5.  [Problems in the determination of isoelectric points of beta lactamases].

Authors:  R Labia; M Barthélémy
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1977-05-02

6.  Plasmid-linked ampicillin resistance in haempohilus influenza type b.

Authors:  L P Elwell; J De Graaff; D Seibert; S Falkow
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

7.  Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine.

Authors:  R Norrby; J E Brorsson; S Seeberg
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

9.  Antibacterial activity of cefuroxime, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cefamandole.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

10.  Escherichia coli K-12 mutants hyperproducing chromosomal beta-lactamase by gene repetitions.

Authors:  S Normark; T Edlund; T Grundström; S Bergström; H Wolf-Watz
Journal:  J Bacteriol       Date:  1977-12       Impact factor: 3.490

View more
  14 in total

1.  The polar effect on nifM of mutations in the nifU,-S,-V genes of Klebsiella pneumoniae depends on their plasmid or chromosomal location.

Authors:  L Sibold
Journal:  Mol Gen Genet       Date:  1982

2.  Antibacterial activity of a new parenteral cephalosporin--HR 756: comparison with cefamandole and ceforanide.

Authors:  G W Counts; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

3.  Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.

Authors:  J LeFrock; J Mader; B Smith; B Carr
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Antibacterial and plasmid curing activity of lomefloxacin in vitro.

Authors:  E Derlot; C Poyart-Salmeron; P Courvalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

5.  In vitro antimicrobial activity of cefotaxime, a new cephalosporin.

Authors:  S Masuyoshi; S Arai; M Miyamoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

6.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

7.  Role of porin proteins OmpF and OmpC in the permeation of beta-lactams.

Authors:  A Jaffe; Y A Chabbert; O Semonin
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

8.  Des-, syn- and anti-oxyimino-delta 3-cephalosporins. Intrinsic reactivity and reaction with RTEM-2 serine beta-lactamase and D-alanyl-D-alanine-cleaving serine and Zn2+-containing peptidases.

Authors:  G Laurent; F Durant; J M Frere; D Klein; J M Ghuysen
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

9.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

Authors:  R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.